ARCTURUS AIMING FOR 10 DERMATOLOGICALS IN CLINICALS BY 1997
Executive Summary
ARCTURUS AIMING FOR 10 DERMATOLOGICALS IN CLINICALS BY 1997 as a result of a licensing agreement with Boston's Beth Israel Hospital, which gives the start-up firm the right of first refusal to dermatological inventions from the labs of Arcturus cofounders Kenneth Arndt, MD, and Stephen Galli, MD. Galli is chairman of the firm's scientific advisory board as well as director of Beth Israel's division of experimental pathology and associate professor of pathology at Harvard Medical School. Arndt is chairman of Beth Israel's dermatology department and professor of dermatology at Harvard. Arcturus says it hopes to create "a new generation of innovative therapeutic agents" based on "advances in skin biology" as well as a proprietary delivery technology. The Woburn, Mass.- based firm has three products in preclinical studies, the most advanced of which is a topical antipruritic for treatment of atopic dermatitis. Other product candidates include a topical anesthetic for use in laser surgery and cryosurgery and a potential alternative to topical corticosteroids that treats immunologically-mediated skin disorders by inhibiting specific hypersensitivity reactions. Arcturus is also researching compounds for acne and hair loss. The four-year-old firm announced the completion of a $3.5 mil. first round venture financing July 23. Financing participants included Dillon, Read; Commonwealth BioVentures; and BancBoston Ventures. Arcturus was founded in March 1988 by Galli, Arndt and Arcturus VP-R&D Richard Sharpe, MD. Sharpe was previously a researcher for Repligen. Arcturus President and CEO Dana Ono, PhD, joined from Enzytech, where he was VP-business development. Ono is the author of The Business of Biotechnology -- From the Bench to the Street.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth